Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 8-K (Current Report)
Date of Report: January 18, 2024
Reporting Period: Event-based report regarding a corporate action effective January 22, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a capital structure modification.
Material Changes
The Company implemented a 1-for-20 reverse stock split of its issued and outstanding common stock. Key details include:
- Effective Date: 12:01 a.m. Eastern Time on January 22, 2024.
- Conversion Ratio: Every 20 shares of Common Stock were converted into 1 share.
- Trading Status: Trading on the Nasdaq Capital Market resumed on a split-adjusted basis under the symbol "PCSA" with a new CUSIP number (74275C304).
- Fractional Shares: No fractional shares were issued; holders entitled to fractions received shares rounded up to the nearest whole number.
- Authorized Shares: The total number of authorized shares (100,000,000) and par value ($0.0001) remain unchanged.
- Derivatives: Outstanding options, warrants, and restricted stock units were adjusted proportionally.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure that the summary of the Certificate of Amendment is qualified by reference to the full text of the document filed as Exhibit 3.1.
Investor Verification Checklist
- Verify the new CUSIP number (74275C304) for accurate trading and record-keeping.
- Confirm the adjustment of any outstanding options, warrants, or RSUs held in brokerage accounts.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.
- Check the press release (Exhibit 99.1) for additional context on the rationale for the reverse split.